采用α－干扰素（α－ＩＦＮ）、病毒唑联合治疗慢性ＨＢＶ感染病人６３例，以α－ＩＦＮ治疗慢性乙肝病人５８例，对比观察联合用药对病人血清ＨＢｅＡｇ、Ｐｒｅ－Ｓ２、ＰＨＳＡ－Ｒ及ＤＮＡ－Ｐ复制指标的抑制效应．３个月疗程结束后，抑制效应两组分别为ＨＢｅＡｇ４９．２％和３４．５％；Ｐｒｅ－Ｓ２５２．７％和３８．８％；ＰＨＳＡ－Ｒ４４．２％和３７．７％；ＤＮＡ－Ｐ５７．９％和４１．９％；高复制型５２．６％和４０％，除ＰＨＳＡＲ外，两组比较差异有显著性，联合用药组优于α－ＩＦＮ组。 Sixty-three patients with chronic HBV infection were treated with α-interferon (IFN-α) and ribavirin and 58 patients with chronic hepatitis B (IFN-α) were treated with α-IFN. The levels of HBeAg, Pre-S2, PHSA- Inhibitory effect of DNA-P replication index. After 3 months of treatment, the inhibitory effects were HBeAg 49.2% and 34.5% in both groups; Pre-S252.7% and 38.8%; PHSA-R44.2% and 37.7%; DNA-P57 .9% and 41.9%, respectively; high-copy 52.6% and 40%, except for PHSAR, the difference between the two groups was significant, and the combination group was superior to the α-IFN group.